The Aging Body’s Hidden Brake: Scientists Discover a Glycolytic Metabolite That Suppresses Chronic Inflammation

A 2026 Nature Aging study reveals that a common energy metabolite acts as a natural suppressor of the body’s most powerful aging inflammatory circuit — and that its decline may be one of the clearest metabolic signatures of biological aging.

Presented By Our Partners

Every cell in your body is running a continuous energy calculation. Glucose enters, gets broken down through glycolysis, and the resulting molecules power everything from muscle contraction to DNA repair. Scientists have long known that this metabolic machinery shifts profoundly with age. What they did not know — until now — is that one intermediate in that ancient energy pathway also quietly keeps your immune system from setting your tissues on fire.

A landmark study published in Nature Aging in 2026 by Song, Hu, Zhang, and colleagues has identified phosphoenolpyruvate (PEP), a molecule produced midway through glycolysis, as an endogenous inhibitor of the cGAS-STING pathway: the innate immune circuit now understood to be a primary engine of the chronic, low-grade inflammation that drives biological aging. The researchers found that PEP levels follow a biphasic trajectory across a lifetime, accumulating initially, then declining steadily in later life. That decline, the data suggests, is not a passive side effect of aging. It is a causal driver of it.

What Is the cGAS-STING Pathway and Why Scientists Consider It the “Master Switch” of Inflammaging

To understand why this discovery matters, it helps to understand what the cGAS-STING pathway does and why so much aging research has converged on it over the past decade.

The cyclic GMP-AMP synthase (cGAS) protein is the innate immune system’s primary sensor of cytosolic DNA: DNA that should not be floating free inside a cell. Under normal circumstances, DNA stays safely packaged inside the nucleus or in mitochondria. But as cells age, accumulate damage, or become senescent, DNA leaks into the cytoplasm — fragments from eroded telomeres, from dysfunctional mitochondria, from double-strand breaks that were never repaired. cGAS detects this mislocated DNA and responds by producing cyclic GMP-AMP (cGAMP), a second messenger that activates its downstream partner, STING (stimulator of interferon genes).

Once STING is activated, it triggers two major inflammatory cascades. The first activates TANK-binding kinase 1 (TBK1), which phosphorylates interferon regulatory factor 3 (IRF3) and drives the production of type I interferons. The second releases nuclear factor kappa-B (NF-kB), one of the most studied pro-inflammatory transcription factors in medicine, which floods cells with cytokines including interleukin-6, TNF-alpha, and interleukin-1 beta.

In youth, this system is essential. It detects genuine threats — viral DNA, bacterial invasion, genomic instability in precancerous cells — and orchestrates a proportionate immune response. But in aging, the system loses its calibration. Cytosolic DNA accumulates faster than it can be cleared. The cGAS-STING pathway fires persistently, even in the absence of actual infection, generating the chronic inflammatory background that researchers now call “inflammaging”: a smoldering immune activation that is increasingly linked to cardiovascular disease, neurodegeneration, metabolic dysfunction, and accelerated cellular senescence.

A landmark 2023 study in Nature established that cGAS-STING signaling is a critical driver of age-related neurodegeneration. Subsequent research in Frontiers in Immunology and PNAS confirmed that the pathway is chronically hyperactivated in aged tissues and that suppressing it extends healthspan in multiple animal models. The challenge has been identifying how the body normally keeps cGAS in check — and why that regulation breaks down with age.

That is precisely what the new Nature Aging study answers.

Phosphoenolpyruvate: The Glycolytic Checkpoint Nobody Was Watching

Phosphoenolpyruvate sits near the end of glycolysis, the ten-step metabolic pathway through which cells convert glucose into pyruvate to generate ATP. In the second-to-last step, the enzyme enolase converts 2-phosphoglycerate into PEP. Then, in the final step, pyruvate kinase transfers PEP’s phosphate group to ADP, producing pyruvate and ATP.

PEP has been well-characterized as an energy metabolite since the mid-20th century. It also appeared in 2015 research as a metabolic checkpoint in anti-tumor T cell responses, where it was found to sustain T cell persistence in glucose-limited tumor microenvironments. But its role in innate immune regulation had not been explored.

Song and colleagues approached this from an unexpected angle: they were examining how metabolic changes in aging might explain altered innate immune activation, and they identified PEP as a molecule whose abundance correlated strongly with healthy aging phenotypes in both mice and humans. Working backward from that correlation, they discovered the mechanism: PEP binds directly and competitively to cGAS, blocking the enzyme’s ability to detect cytosolic DNA and produce the cGAMP signal that activates STING.

In other words, PEP does not suppress inflammation by blocking a downstream cytokine. It works at the sensing level — intercepting the alarm before it can ring. When PEP levels are high, cGAS is partially occupied, its activity attenuated. When PEP levels fall, cGAS becomes increasingly free to detect the accumulating cytosolic DNA that is a natural consequence of aging, and the inflammatory signal amplifies.

A Biphasic Decline: How PEP Tracks the Arc of Biological Aging

One of the most striking findings in the paper is the characterization of PEP’s longitudinal trajectory. Using both mouse models and human cohort data, the researchers found that PEP does not simply decrease with age. Instead, it follows a biphasic pattern: levels accumulate through early and middle life, peak, and then undergo a progressive, measurable decline into old age.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

This biphasic arc matches remarkably well with the known trajectory of inflammaging and metabolic health in humans. Metabolic efficiency peaks in early adulthood, glycolytic flux and mitochondrial function remain robust through midlife, and then a confluence of changes — declining muscle mass, reduced mitochondrial density, impaired glucose uptake — gradually erodes the metabolic machinery that generates PEP.

The researchers tested the causal significance of this trajectory through two complementary experiments. In the first, they pharmacologically blocked PEP accumulation in younger mice, preventing it from reaching its natural peak. These animals showed earlier-onset inflammatory activation, accelerated aging phenotypes, and worse metabolic profiles than controls, confirming that the initial accumulation of PEP is not incidental but protective.

In the second experiment, they administered PEP to older mice before its natural decline became severe. These animals showed attenuated cGAS-STING activity, lower levels of pro-inflammatory cytokines, and healthier aging trajectories compared to untreated aged controls. Critically, the benefit was prophylactic: PEP was most effective when given before the decline, not after it was already well established. This timing point carries significant translational implications, suggesting that interventions aimed at sustaining metabolic PEP production during midlife may have outsized long-term effects on healthspan.

Human Data: PEP Levels Predict Inflammation and Healthy Aging Traits

The study did not stop at animal models. In analyses of aged human cohorts, the researchers found that individuals with higher circulating PEP levels showed significantly lower markers of chronic inflammation, including C-reactive protein, interleukin-6, and other canonical inflammaging biomarkers. High PEP correlated with healthier metabolic profiles, better cognitive scores, and lower biological age as assessed by established epigenetic clock measures.

This is not a trivial finding. Most molecular biology studies report animal results and extrapolate cautiously to human relevance. The correlation between PEP levels and healthy aging traits in actual human subjects provides early validation that the mechanism is not confined to mouse physiology. It also opens the door to PEP as a potential biomarker of metabolic and inflammatory health in clinical aging research — a molecule that might one day appear alongside glucose, insulin, and CRP on a longevity-focused metabolic panel.

The Alzheimer’s Connection: Cognition Restored in Disease Models

Perhaps the most immediately striking clinical finding in the paper is the Alzheimer’s disease data. When PEP was administered to mice carrying Alzheimer’s disease pathology, it reduced neuroinflammation and improved cognitive performance on memory and spatial navigation tasks.

This fits precisely with what researchers have come to understand about Alzheimer’s neurobiology. The cGAS-STING pathway is highly active in aged microglia, the brain’s resident immune cells, where it drives the production of neuroinflammatory mediators that damage synaptic connections and accelerate the clearance of still-functional neurons. A 2024 study in Frontiers in Aging Neuroscience found that cGAS-STING signaling components are significantly elevated in the cortex and hippocampus of aging mice, independent of Alzheimer’s-specific pathology. When Alzheimer’s-related damage is layered onto this already-hyperactivated baseline, the inflammatory cascade compounds.

PEP’s ability to suppress cGAS activity at the source means it could, in principle, reduce this compounding neuroinflammatory burden. The cognitive improvements seen in the Alzheimer’s mouse models suggest the effect is functionally meaningful, not merely a biochemical curiosity. Researchers will need to validate this in human trials, but the mechanistic logic is compelling and consistent with the broader cGAS-STING literature on neurodegeneration.

This finding also connects to Healthcare Discovery’s coverage of the brain’s glymphatic drainage system — the recently characterized lymphatic network, including the middle meningeal artery hub, through which the brain clears amyloid-beta and tau proteins during sleep. Neuroinflammation driven by cGAS-STING impairs glymphatic flow and accelerates protein aggregation, while metabolic health and sleep are among the most powerful modulators of both PEP production and glymphatic clearance. The mechanisms are converging.

What This Means for Metabolic Health, Exercise, and the Five Pillars

The clinical implications of this research extend well beyond a potential future pharmaceutical. PEP is not an exotic molecule requiring laboratory synthesis. It is produced in every cell that runs glycolysis — which is to say, every cell in your body, every day, every time you eat, move, and breathe.

Several lifestyle factors are known to influence glycolytic flux and glycolytic metabolite abundance. Resistance training and high-intensity interval exercise both enhance glycolytic capacity significantly. Studies published in the American Journal of Physiology and PMC have shown that interventions increasing muscle mass and glycolytic enzyme expression improve systemic metabolic homeostasis and insulin sensitivity. Given that PEP is a direct product of glycolysis, it is reasonable to hypothesize that maintaining glycolytic capacity through exercise may be one mechanism by which physical activity exerts its anti-inflammatory and neuroprotective effects — effects that have been extensively documented in the exercise science literature but whose molecular mediators have remained incompletely characterized.

Blood sugar stability is also relevant here. Chronic hyperglycemia — the metabolic signature of insulin resistance and type 2 diabetes — does not increase PEP production proportionally with increased glucose availability. In fact, metabolic dysregulation disrupts the precise enzymatic coordination that governs glycolytic flux, and PEP’s conversion by pyruvate kinase is subject to allosteric regulation that can be impaired in metabolic disease states. Sustaining the metabolic health of the cells that produce PEP may matter as much as the availability of glucose substrate.

Nutritional factors also enter the picture. Glucose metabolism and the glycolytic pathway are directly influenced by B-vitamin status — particularly thiamine (B1), riboflavin (B2), and niacin (B3) — as well as magnesium, which is essential for multiple glycolytic enzymes. The integrity of the gut microbiome influences systemic metabolite levels and metabolic inflammation, connecting this discovery to the rapidly expanding field of microbiome-longevity research. Sleep, one of the most powerful regulators of metabolic health, restores glycolytic efficiency and reduces inflammatory cytokine burden during the nighttime repair window.

None of these connections have been experimentally tested against PEP specifically in the context of cGAS-STING modulation. The Song et al. study is a foundational mechanistic paper, not a lifestyle intervention trial. But the biological logic is solid, and it reinforces a principle that appears across multiple fronts of longevity science: the same foundational behaviors — consistent movement, blood sugar stability, adequate sleep, micronutrient sufficiency — protect health through multiple converging mechanisms, many of which are still being discovered.

What the Research Community Is Saying

The companion commentary published alongside the original paper in Nature Aging, titled “A glycolytic metabolite puts the brakes on cGAS-driven aging,” describes PEP as “a previously unrecognized molecular bridge between cellular metabolism and innate immune homeostasis in aging.” The commentators highlight the biphasic trajectory finding as particularly significant, noting that it implies a window for intervention during midlife before the protective accumulation reverses.

This timing insight resonates with the broader concept of Longevity Escape Velocity — the idea that staying biologically healthy through midlife positions individuals to benefit from the accelerating wave of precision interventions arriving over the next decade. If PEP levels are highest in early and middle adulthood and begin declining thereafter, the most effective window for protecting cGAS-STING regulation through lifestyle-based metabolic optimization may be precisely the years when most people are not yet thinking seriously about longevity medicine.

The cGAS-STING field has already attracted significant pharmaceutical interest. Several biotech companies are developing small-molecule cGAS inhibitors for indications ranging from autoimmune disease to neurodegeneration. The discovery that the body produces its own endogenous cGAS inhibitor through central metabolic pathways adds a new dimension to this drug development landscape: it raises the question of whether future senostatic or anti-inflammaging interventions might target PEP production or delivery rather than the cGAS protein itself.

What This Means for You

You cannot yet take a PEP supplement and expect it to suppress your inflammaging cascade — the pharmacokinetics of delivering a glycolytic intermediate to aging tissues in a therapeutically meaningful way are genuinely complex, and human trials have not been conducted. But this research gives a sharper mechanistic rationale for behaviors that longevity science has long recommended:

Preserve your glycolytic capacity through consistent resistance training and metabolically demanding exercise. Muscle is the largest glycolytic tissue in the body, and its metabolic fitness directly influences the abundance and flux of metabolites like PEP throughout the system. A 2026 American Physiological Society review confirmed that glycolytic capacity is among the most responsive metrics to structured exercise, reversible even in older adults who begin training later in life.

Prioritize blood sugar stability, not just as a diabetes prevention strategy but as a core metabolic health practice. Chronic glycemic dysregulation impairs the enzymatic coordination that governs glycolysis, potentially disrupting the PEP production that the new Nature Aging study identifies as a protective factor in healthy aging.

Sleep adequately and consistently. Metabolic waste clearance, mitochondrial repair, and the suppression of cytosolic DNA accumulation all occur primarily during sleep. Chronic sleep disruption accelerates precisely the conditions that drive cGAS activation — mitochondrial DNA release, telomeric damage, senescent cell accumulation — while impairing the metabolic health that sustains PEP production.

Track your inflammatory biomarkers. While PEP is not yet a standard clinical test, CRP, IL-6, and biological age clocks are increasingly accessible through direct-to-consumer and clinical labs. Monitoring inflammaging markers over time provides a real-world window into whether your lifestyle behaviors are keeping the cGAS-STING system appropriately suppressed.

The Nature Aging paper by Song, Hu, Zhang and colleagues is not the final word on PEP biology or on the cGAS-STING pathway in aging. It is a precise, mechanistically rigorous opening of a new chapter. The chapter is about what the body already does to protect itself from its own aging — and what happens when the metabolic resources that power that protection are allowed to erode. The answer, it turns out, is written into the oldest energy pathway in biology.

Sources: Song Z, Hu H, Zhang W et al. “The glycolytic metabolite phosphoenolpyruvate restricts cGAS-driven inflammation to promote healthy aging.” Nature Aging, 2026. DOI: 10.1038/s43587-026-01087-1. Gulen MF et al. “cGAS-STING drives ageing-related inflammation and neurodegeneration.” Nature, 2023. DOI: 10.1038/s41586-023-06373-1. Frontiers in Immunology, “cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging,” 2023. Frontiers in Aging Neuroscience, “Alteration of cGAS-STING signaling pathway components in the mouse cortex and hippocampus during healthy brain aging,” 2024. American Journal of Physiology, “Metabolic benefits of resistance training and fast glycolytic skeletal muscle,” 2011.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.